A tricyclic pentaglycosidic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA. It is used as a fluorescent dye and as an antineoplastic agent, especially in bone and testicular tumors. Plicamycin is also used to reduce hypercalcemia, especially that due to malignancies.
Glycosidic antibiotic from Streptomyces griseus used as a fluorescent stain of DNA and as an antineoplastic agent.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
A complex of several closely related glycosidic antibiotics from Streptomyces griseus. The major component, CHROMOMYCIN A3, is used as a fluorescent stain of DNA where it attaches and inhibits RNA synthesis. It is also used as an antineoplastic agent, especially for solid tumors.
A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.
A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.
Abnormally high level of calcium in the blood.
Medicines that can be sold legally without a DRUG PRESCRIPTION.
Libraries in which a major proportion of the resources are available in machine-readable format, rather than on paper or MICROFORM.
Books used in the study of a subject that contain a systematic presentation of the principles and vocabulary of a subject.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
Products in capsule, tablet or liquid form that provide dietary ingredients, and that are intended to be taken by mouth to increase the intake of nutrients. Dietary supplements can include macronutrients, such as proteins, carbohydrates, and fats; and/or MICRONUTRIENTS, such as VITAMINS; MINERALS; and PHYTOCHEMICALS.
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.

Interaction of the DNA-binding antitumor antibiotics, chromomycin and mithramycin with erythroid spectrin. (1/164)

The aureolic acid group of antitumor antibiotics, chromomycin A3 and mithramycin, are well established as transcription inhibitors, which bind reversibly to DNA at and above physiological pH, in the presence of divalent metal ions such as Mg2+. As part of our broad objective to elucidate their intracellular mode of action, other than association with DNA, we studied their interactions with the erythrocyte cytoskeletal protein, spectrin, in the absence and presence of magnesium. Different spectroscopic studies, such as absorbance, fluorescence and CD, have shown that both free chromomycin and mithramycin and their Mg2+ complexes bind to spectrin with an affinity higher than that reported for DNA. The affinity constants for the association of chromomycin and mithramycin (or their Mg2+ complexes) with spectrin are comparable with those for the association of spectrin with other cytoskeletal proteins, for example F-actin, ankyrin, protein 4.1, etc. The nature of the binding of the two antibiotics to spectrin is different. The mode of binding of the antibiotics with spectrin also changes in the presence of Mg2+. The interaction leads to a change in the tertiary structure of the protein. The relevance of the results to our understanding of the mode of action of the antibiotics is discussed.  (+info)

Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin by Streptomyces argillaceus. (2/164)

A DNA chromosomal region of Streptomyces argillaceus ATCC 12596, the producer organism of the antitumor polyketide drug mithramycin, was cloned. Sequence analysis of this DNA region, located between four mithramycin glycosyltransferase genes, showed the presence of two genes (mtmMI and mtmMII) whose deduced products resembled S-adenosylmethionine-dependent methyltransferases. By independent insertional inactivation of both genes nonproducing mutants were generated that accumulated different mithramycin biosynthetic intermediates. The M3DeltaMI mutant (mtmMI-minus mutant) accumulated 4-demethylpremithramycinone (4-DPMC) which lacks the methyl groups at carbons 4 and 9. The M3DeltaM2 (mtmMII-minus mutant) accumulated 9-demethylpremithramycin A3 (9-DPMA3), premithramycin A1 (PMA1), and 7-demethylmithramycin, all of them containing the O-methyl group at C-4 and C-1', respectively, but lacking the methyl group at the aromatic position. Both genes were expressed in Streptomyces lividans TK21 under the control of the erythromycin resistance promoter (ermEp) of Saccharopolyspora erythraea. Cell-free extracts of these clones were precipitated with ammonium sulfate (90% saturation) and assayed for methylation activity using different mithramycin intermediates as substrates. Extracts of strains MJM1 (expressing the mtmMI gene) and MJM2 (expressing the mtmMII gene) catalyzed efficient transfer of tritium from [(3)H]S-adenosylmethionine into 4-DPMC and 9-DPMA3, respectively, being unable to methylate other intermediates at a detectable level. These results demonstrate that the mtmMI and mtmMII genes code for two S-adenosylmethionine-dependent methyltransferases responsible for the 4-O-methylation and 9-C-methylation steps of the biosynthetic precursors 4-DPMC and 9-DPMA3, respectively, of the antitumor drug mithramycin. A pathway is proposed for the last steps in the biosynthesis of mithramycin involving these methylation events.  (+info)

Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. (3/164)

DNA-binding drugs have been reported to be able to interfere with the activity of transcription factors in a sequence-dependent manner, leading to alteration of transcription. This and similar effects could have important practical applications in the experimental therapy of many human pathologies, including neoplastic diseases and viral infections. The analysis of the biological activity of DNA-binding drugs by footprinting, gel retardation, polymerase chain reaction, and in vitro transcription studies does not allow a real time study of binding to DNA and dissociation of the generated drugs/DNA complexes. The recent development of biosensor technologies for biospecific interaction analysis (BIA) enables monitoring of a variety of molecular reactions in real-time by surface plasmon resonance (SPR). In this study, we demonstrate that molecular interactions between DNA-binding drugs (chromomycin, mithramycin, distamycin, and MEN 10567) and biotinylated target DNA probes immobilized on sensor chips is detectable by SPR technology using a commercially available biosensor. The target DNA sequences were synthetic oligonucleotides mimicking the Sp1, NF-kB, and TFIID binding sites of the long terminal repeat of the human immunodeficiency type 1 virus. The results obtained demonstrate that mithramycin/DNA complexes are less stable than chromomycin/DNA complexes; distamycin binds to both NF-kB and TATA box oligonucleotides, but distamycin/(NF-kB)DNA complexes are not stable; the distamycin analog MEN 10567 binds to the NF-kB mer and the generated drug/DNA complexes are stable. The experimental approach described in this study allows fast analysis of molecular interactions between DNA-binding drugs and selected target DNA sequences. Therefore, this method could be used to identify new drugs exhibiting differential binding activities to selected regions of viral and eukaryotic gene promoters.  (+info)

Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. (4/164)

OBJECTIVE: To determine the potential roles of transcription factors Sp1 and Sp3 in the increased expression of the human alpha2(I) collagen gene in scleroderma fibroblasts. METHODS: Dermal fibroblasts from 7 patients with diffuse systemic sclerosis (SSc; scleroderma) of recent onset and from 7 healthy individuals were studied. The levels of expression of alpha2(I) procollagen, Sp1, and Sp3 messenger RNA (mRNA), with or without stimulation by transforming growth factor beta (TGFbeta) or oncostatin M (OSM), were evaluated by Northern blot analysis, and the respective protein levels were determined by immunoblotting. The DNA binding activity of nuclear proteins recognizing the cis-acting elements in the human alpha2(I) collagen promoter was examined by gel mobility shift assays. The levels of Sp1 phosphorylation were investigated by immunoprecipitation using an antiphosphoserine-specific antibody. RESULTS: SSc fibroblasts showed basal alpha2(I) collagen mRNA levels that were approximately 3 times higher than those in normal fibroblasts. TGFbeta or OSM increased human alpha2(I) collagen mRNA expression in normal dermal fibroblasts, but these cytokines failed to increase alpha2(I) collagen mRNA levels in SSc fibroblasts. There were no significant differences in the levels of expression of Sp1 or Sp3 between SSc and normal fibroblasts. However, increased Sp1 phosphorylation was detected in SSc fibroblasts compared with normal fibroblasts. Mithramycin, a specific inhibitor of Sp1 binding, abolished the increased expression of the alpha2(I) collagen gene in SSc fibroblasts, in a dose-dependent manner. CONCLUSION: These results demonstrate the involvement of Sp1 in the up-regulation of expression of the alpha2(I) collagen gene in SSc fibroblasts.  (+info)

Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. (5/164)

The mechanism(s) by which Smads mediate and modulate the transforming growth factor (TGF)-beta signal transduction pathway in fibrogenesis are not well characterized. We previously showed that Smad3 promotes alpha2(I) collagen gene (COL1A2) activation in human glomerular mesangial cells, potentially contributing to glomerulosclerosis. Here, we report that Sp1 binding is necessary for TGF-beta1-induced type I collagen mRNA expression. Deletion of three Sp1 sites (GC box) between -376 and -268 or mutation of a CAGA box at -268/-260 inhibited TGF-beta1-induced alpha2(I) collagen promoter activity. TGF-beta1 inducibility was also blocked by a Smad3 dominant negative mutant. Chemical inhibition of Sp1 binding with mithramycin A, or deletion of the GC boxes, inhibited COL1A2 activation by Smad3, suggesting cooperation between Smad3 and Sp1 in the TGF-beta1 response. Electrophoretic mobility shift assay showed that Sp1 and Smads form complexes with -283/-250 promoter sequences. Coimmunoprecipitation experiments demonstrate that endogenous Sp1, Smad3, and Smad4 form complexes in mesangial cells. In a Gal4-LUC reporter assay system, Sp1 stimulated the TGF-beta1-induced transcriptional activity of Gal4-Smad3, Gal4-Smad4 (266), or both. Using the transactivation domain B of Sp1 fused to the Gal4 DNA binding domain, we show that, in our system, the transcriptional activity of this Sp1 domain is not regulated by TGF-beta1, but it becomes responsive to this factor when Smad3 is coexpressed. Finally, combined Sp1 and Smad3 overexpression induces marked ligand-independent and ligand-dependent promoter activity of COL1A2. Thus, Sp1 and Smad proteins form complexes and their synergy plays an important role in mediating TGF-beta1-induced alpha2(I) collagen expression in human mesangial cells.  (+info)

The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters. (6/164)

Modulation of mucin gene expression is an important component both in the early steps of colon cancer development and in later tumor progression. Previous work from our laboratory and others has suggested that the Sp family of transcription factors may play an important role in the regulation of the human MUC2 gene. To determine whether this was an essential element, we extended our work to the cloning and analysis of 3.5 kb of the 5'-flanking region of the mouse Muc2 (mMuc2) gene. Comparative analysis between the mouse and human MUC2 promoter regions has identified a strong sequence homology between the mouse and human genes, including the presence of GC-rich boxes, the location and composition of which are maintained in the mouse and human genes. We show that these GC boxes are binding sites for Sp-family transcription factors and are functionally important since mithramycin, an inhibitor of Sp1/Sp3 binding, blocks MUC2 gene expression in HT29 cells. Furthermore, by a combination of gel shift analysis and site-directed mutagenesis, we have identified the relative contribution of individual GC boxes, and of the factors they bind, to the regulation of the mouse Muc2 promoter, which appears to be different in the mouse and human genes. Finally, we demonstrate by overexpressing Sp1 and Sp3 that the functional difference between the proximal promoter region of the MUC2 gene in the two species is not attributable to differential ability of this region to bind members of the Sp family of transcription factors, but rather to the different anatomy of the individual GC boxes in the mouse and human proximal promoters.  (+info)

Sp1 involvement in the 4beta-phorbol 12-myristate 13-acetate (TPA)-mediated increase in resistance to methotrexate in Chinese hamster ovary cells. (7/164)

4beta-Phorbol 12-myristate 13-acetate (TPA) increases the number of colonies resistant to methotrexate (MTX), mainly by amplification of the dihydrofolate reductase (dhfr) locus. We showed previously that inhibition of protein kinase C (PKC) prevents this resistance. Here, we studied the molecular changes involved in the development of TPA-mediated MTX resistance in Chinese hamster ovary (CHO) cells. TPA incubation increased the expression and activity of DHFR. Because Sp1 controls the dhfr promoter, we determined the effect of TPA on the expression of Sp1 and its binding to DNA. TPA incubation increased Sp1 binding and the levels of Sp1 protein. The latter effect was due to an increase in Sp1 mRNA. Dephosphorylation of nuclear extracts from control or TPA-treated cells reduced the binding of Sp1. Stable transfectants of PKCalpha showed increased Sp1 binding, and when treated with MTX, developed a greater number of resistant colonies than control cells. Seventy-five percent of the isolated colonies showed increased copy number for the dhfr gene. Transient expression of PKCalpha increased DHFR activity. Over-expression of Sp1 increased resistance to MTX, and inhibition of Sp1 binding by mithramycin decreased this resistance. We conclude that one mechanism by which TPA enhances MTX resistance, mainly by gene amplification, is through an increase in Sp1 expression which leads to DHFR activation.  (+info)

Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. (8/164)

The pancreatic cancer cell line, MIA PaCa-2 is not responsive to transforming growth factor beta (TGF-beta) because of a lack of expression of the TGF-beta type II receptor (RII). We show that the lack of RII expression is caused by a deficit of the transcription factor Sp1. Nuclear run-off assays and Western immunoblot showed low levels of transcription and protein levels of Sp1, respectively. Treatment of MIA PaCa-2 cells with the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine, resulted in an increase in the rate of Sp1 transcription, in Sp1 protein expression, and in the binding of Sp1 to the RII promoter. Ectopic expression of Sp1 cDNA in MIA PaCa-2 cells led to an increase in RII promoter-chloramphenicol acetyltransferase activity and RII expression. Expression of Sp1 cDNA also caused a reduction in both growth and clonogenicity that was associated with restoration of responsiveness to TGF-beta. Conversely, cells that express RII (BxPC-3 and MIA PaCa-2 Sp1 transfectants) when treated with mithramycin, an inhibitor of Sp1 binding, showed a reduction in RII mRNA expression. The reduction of RII mRNA was attributed to a decrease in RII promoter-chloramphenicol acetyltransferase activity that was associated with a decrease in Sp1 binding to the RII promoter. These data indicate that transcriptional repression of the Sp1 gene in MIA PaCa-2 cells plays a role in the transcriptional inactivation of the RII gene and thus lack of responsiveness to TGF-beta.  (+info)

Plicamycin, also known as Mithramycin, is an antineoplastic antibiotic derived from Streptomyces plicatus. It works by intercalating into DNA and inhibiting RNA polymerase, which leads to the suppression of gene expression and ultimately results in the death of rapidly dividing cells. Plicamycin has been used in the treatment of testicular cancer, hypercalcemia of malignancy, and certain types of bone tumors. It is administered intravenously and its use is associated with a number of potential side effects, including kidney damage, liver toxicity, and bone marrow suppression.

Chromomycin A3 is an antibiotic and a DNA-binding molecule that is used in research and scientific studies. It is a type of glycosylated anthracycline that can intercalate into DNA and inhibit DNA-dependent RNA synthesis. Chromomycin A3 has been used as a fluorescent stain for microscopy, particularly for the staining of chromosomes during mitosis. It is also used in molecular biology research to study the interactions between drugs and DNA.

It's important to note that Chromomycin A3 is not used as a therapeutic drug in human or veterinary medicine due to its toxicity, it's mainly used for research purposes.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

Chromomycins are a group of antibiotics that are produced by the bacterium Streptomyces griseus. They are known for their ability to bind to DNA and inhibit the growth of various bacteria, fungi, and parasites. Chromomycins have been studied for their potential use in cancer treatment due to their antiproliferative effects on certain types of tumor cells. However, they have not yet been approved for clinical use in humans.

Streptomyces is a genus of Gram-positive, aerobic, saprophytic bacteria that are widely distributed in soil, water, and decaying organic matter. They are known for their complex morphology, forming branching filaments called hyphae that can differentiate into long chains of spores.

Streptomyces species are particularly notable for their ability to produce a wide variety of bioactive secondary metabolites, including antibiotics, antifungals, and other therapeutic compounds. In fact, many important antibiotics such as streptomycin, neomycin, tetracycline, and erythromycin are derived from Streptomyces species.

Because of their industrial importance in the production of antibiotics and other bioactive compounds, Streptomyces have been extensively studied and are considered model organisms for the study of bacterial genetics, biochemistry, and ecology.

Osteitis deformans, also known as Paget's disease of bone, is a chronic disorder of the bone characterized by abnormal turnover and remodeling of the bone. In this condition, the bone becomes enlarged, thickened, and deformed due to excessive and disorganized bone formation and resorption.

The process begins when the bone-remodeling cycle is disrupted, leading to an imbalance between the activity of osteoclasts (cells that break down bone) and osteoblasts (cells that form new bone). In Paget's disease, osteoclasts become overactive and increase bone resorption, followed by an overzealous response from osteoblasts, which attempt to repair the damage but do so in a disorganized manner.

The affected bones can become weakened, prone to fractures, and may cause pain, deformities, or other complications such as arthritis, hearing loss, or neurological symptoms if the skull or spine is involved. The exact cause of Paget's disease remains unknown, but it is believed that genetic and environmental factors play a role in its development.

Early diagnosis and treatment can help manage the symptoms and prevent complications associated with osteitis deformans. Treatment options include medications to slow down bone turnover, pain management, and orthopedic interventions when necessary.

Hypercalcemia is a medical condition characterized by an excess of calcium ( Ca2+ ) in the blood. While the normal range for serum calcium levels is typically between 8.5 to 10.2 mg/dL (milligrams per deciliter) or 2.14 to 2.55 mmol/L (millimoles per liter), hypercalcemia is generally defined as a serum calcium level greater than 10.5 mg/dL or 2.6 mmol/L.

Hypercalcemia can result from various underlying medical disorders, including primary hyperparathyroidism, malignancy (cancer), certain medications, granulomatous diseases, and excessive vitamin D intake or production. Symptoms of hypercalcemia may include fatigue, weakness, confusion, memory loss, depression, constipation, nausea, vomiting, increased thirst, frequent urination, bone pain, and kidney stones. Severe or prolonged hypercalcemia can lead to serious complications such as kidney failure, cardiac arrhythmias, and calcification of soft tissues. Treatment depends on the underlying cause and severity of the condition.

Nonprescription drugs, also known as over-the-counter (OTC) drugs, are medications that can be legally purchased without a prescription from a healthcare professional. They are considered safe and effective for treating minor illnesses or symptoms when used according to the directions on the label. Examples include pain relievers like acetaminophen and ibuprofen, antihistamines for allergies, and topical treatments for skin conditions. It is still important to follow the recommended dosage and consult with a healthcare provider if there are any concerns or questions about using nonprescription drugs.

A digital library is a collection of digital objects, including text, images, audio, and video, that are stored, managed, and accessed electronically. These libraries can include a variety of resources such as e-books, journal articles, databases, multimedia materials, and other digital assets. They often provide features such as search and retrieval capabilities, as well as tools for organizing, preserving, and protecting the digital content. Digital libraries may be standalone institutions or part of larger organizations, such as universities, hospitals, or research centers. They can serve a variety of purposes, including education, research, and cultural preservation. Access to digital libraries may be open to the public or restricted to authorized users.

"Textbooks as Topic" is a medical subject heading (MeSH) used in the National Library of Medicine's cataloging system to describe works that are about textbooks as a genre or medium, rather than a specific subject. This can include discussions on the history of medical textbooks, their role in medical education, comparisons between different types of textbooks, and analysis of their content and effectiveness. It may also cover issues related to the production, distribution, and accessibility of medical textbooks.

Drug-related side effects and adverse reactions refer to any unintended or harmful outcome that occurs during the use of a medication. These reactions can be mild or severe and may include predictable, known responses (side effects) as well as unexpected, idiosyncratic reactions (adverse effects). Side effects are typically related to the pharmacologic properties of the drug and occur at therapeutic doses, while adverse reactions may result from allergic or hypersensitivity reactions, overdoses, or interactions with other medications or substances.

Side effects are often dose-dependent and can be managed by adjusting the dose, frequency, or route of administration. Adverse reactions, on the other hand, may require discontinuation of the medication or treatment with antidotes or supportive care. It is important for healthcare providers to monitor patients closely for any signs of drug-related side effects and adverse reactions and to take appropriate action when necessary.

Pharmaceutical preparations refer to the various forms of medicines that are produced by pharmaceutical companies, which are intended for therapeutic or prophylactic use. These preparations consist of an active ingredient (the drug) combined with excipients (inactive ingredients) in a specific formulation and dosage form.

The active ingredient is the substance that has a therapeutic effect on the body, while the excipients are added to improve the stability, palatability, bioavailability, or administration of the drug. Examples of pharmaceutical preparations include tablets, capsules, solutions, suspensions, emulsions, ointments, creams, and injections.

The production of pharmaceutical preparations involves a series of steps that ensure the quality, safety, and efficacy of the final product. These steps include the selection and testing of raw materials, formulation development, manufacturing, packaging, labeling, and storage. Each step is governed by strict regulations and guidelines to ensure that the final product meets the required standards for use in medical practice.

A dietary supplement is a product that contains nutrients, such as vitamins, minerals, amino acids, herbs or other botanicals, and is intended to be taken by mouth, to supplement the diet. Dietary supplements can include a wide range of products, such as vitamin and mineral supplements, herbal supplements, and sports nutrition products.

Dietary supplements are not intended to treat, diagnose, cure, or alleviate the effects of diseases. They are intended to be used as a way to add extra nutrients to the diet or to support specific health functions. It is important to note that dietary supplements are not subject to the same rigorous testing and regulations as drugs, so it is important to choose products carefully and consult with a healthcare provider if you have any questions or concerns about using them.

Drug-Induced Liver Injury (DILI) is a medical term that refers to liver damage or injury caused by the use of medications or drugs. This condition can vary in severity, from mild abnormalities in liver function tests to severe liver failure, which may require a liver transplant.

The exact mechanism of DILI can differ depending on the drug involved, but it generally occurs when the liver metabolizes the drug into toxic compounds that damage liver cells. This can happen through various pathways, including direct toxicity to liver cells, immune-mediated reactions, or metabolic idiosyncrasies.

Symptoms of DILI may include jaundice (yellowing of the skin and eyes), fatigue, abdominal pain, nausea, vomiting, loss of appetite, and dark urine. In severe cases, it can lead to complications such as ascites, encephalopathy, and bleeding disorders.

The diagnosis of DILI is often challenging because it requires the exclusion of other potential causes of liver injury. Liver function tests, imaging studies, and sometimes liver biopsies may be necessary to confirm the diagnosis. Treatment typically involves discontinuing the offending drug and providing supportive care until the liver recovers. In some cases, medications that protect the liver or promote its healing may be used.

No data available that match "plicamycin"


Plicamycin has been tested in chronic myeloid leukemia. Plicamycin is currently used in multiple areas of research, including ... Plicamycin has been used in the treatment of testicular cancer, Pagets disease of bone, and, rarely, the management of ... Plicamycin (INN, also known as mithramycin; trade name Mithracin) is an antineoplastic antibiotic produced by Streptomyces ... Dutcher JP, Coletti D, Paietta E, Wiernik PH (May 1997). "A pilot study of alpha-interferon and plicamycin for accelerated ...
Plicamycin has been tested in chronic myeloid leukemia.[7] Plicamycin is currently used in multiple areas of research, ... Plicamycin has been used in the treatment of testicular cancer,[3][4] Pagets disease of bone,[5][6] and, rarely, the ... Plicamycin (INN, also known as mithramycin; trade name Mithracin) is an antineoplastic antibiotic produced by Streptomyces ... plicamycin)". Med. Pediatr. Oncol. 24 (5): 327-8. doi:10.1002/mpo.2950240511. PMID 7700186.. ...
Featuring active ingredients, dosages, related medications, and Plicamycin forums. ... Home › Drugs: P › Plicamycin Plicamycin. Category: Antibiotics. Plicamycin (INN, also known as mithramycin; trade name ...
Find information on Plicamycin (Mithramycin, Mithracin) in Daviss Drug Guide including dosage, side effects, interactions, ... "Plicamycin." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Nursing Central, nursing.unboundmedicine.com/ ... nursingcentral/view/Davis-Drug-Guide/109130/all/plicamycin. Vallerand AHA, Sanoski CAC, Quiring CC. Plicamycin. Daviss Drug ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Plicamycin. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ...
Find information on Plicamycin (Mithramycin, Mithracin) in Daviss Drug Guide including dosage, side effects, interactions, ... "Plicamycin." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Medicine Central, im.unboundmedicine.com/medicine/view/ ... Davis-Drug-Guide/109130/all/plicamycin. Vallerand AHA, Sanoski CAC, Quiring CC. Plicamycin. Daviss Drug Guide. F.A. Davis ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Plicamycin. In Daviss Drug Guide (18th ed.). F.A. Davis Company. https ...
Plicamycin. Most other Common Side Effects: Loss of appetite, nausea, vomiting, diarrhea, mouth ulcer, fever, drowsiness, ...
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above. ...
Plicamycin Plicamycin. 2.5 mg. Chemotherapy Antitumor Antibiotic. Anthracycline. No 1970. 2000. Jan. 1, 1984 In Use. ...
Plicamycin injection. plicamycin - injection. Pneumococc 7-val conj-dip crm intramusc.. pneumococcal pediatric vaccine - ...
Plicamycin (e.g., Mithracin)-Use of these medicines with conjugated estrogens and medroxyprogesterone may increase the chance ...
Gallium and plicamycin have been used to treat hypercalcemia of malignancy, but these compounds have not been used in ...
Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and ... eight additional patients in the blast phase of chronic granulocytic leukemia with a combination of alternate-day plicamycin ...
... plicamycin. 23.1.3.8 protection against micro-organisms, decline of circulating cd5 cells by an as needed diphenhydramine 24mg ...
... plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifin (nolvadex); Taxol (paclitaxel); ...
... enigmata I lambastes readvise nonponderously in accordance with Avodart avolve zyfetor generika rezeptfrei we plicamycin ileal ...
... and plicamycin (made by S. plicatus). Plus we have the anthracyclines daunorubicin and doxorubicin (S. peucetius), and ...
In dieser Liste finden sich die Substanzen (Wirkstoffe) mit einer eindeutigen Zurordnung zu einer systemischen ,Therapieart,. Mehrfachangaben im Feld ,Menge_Substanz, sind möglich.. Die Liste ist für die Nutzung als Vorschlagsliste vorgesehen. Eventuell kann dabei auch eine Vorfilterung nach ,Therapieart, vorgesehen werden, um die Fehler bei der Auswahl einer Substanz weiter zu minimieren.. Die Liste beruht auf dem Register- und Literaturstand August 2021 und erhebt keinen Anspruch auf Vollständigkeit. Es muss für die Dokumentationskraft die Möglichkeit erhalten bleiben, eine nicht in der Liste enthaltene Substanz zu erfassen.. In das Tabellenblatt Substanzen wurde zusätzlich Placebo und Studienmedikament aufgenommen als Platzhalter für unbekannte Wirkstoffe, die im Rahmen einer Studie gegeben werden. Die Substanzen G-CSF und Mesna sind eigentlich keine tumorspezifischen Substanzen, als Bestandteil von Therapieprotokollen wurden sie jedoch in die Liste der Substanzen aufgenommen.. ...
Please wait while your request is being verified ...
Coursers, currentness, provided that uncooperative - dreich plicamycin rx get acarbose a without betwixt prorevision Biedls ...
Plicamycin (Mithracin®). *Procarbazine (Matulane®). *Teniposide (Vumon®). *Trimetrexate (Neutrexin®, TMQ®, TMTX®). *Tretinoin ( ...
Plicamycin (e.g., Mithracin) or. *Ticarcillin (e.g., Ticar) or. *Valproic acid (e.g., Depakene)-Taking these medicines together ...
Mithramycin A (Plicamycin). Oligosaccharide antibiotic, a RNA synthesis inhibitor.. Read more ›. Quote for ...
LiverTox® provides up-to-date, unbiased and easily accessed information on the diagnosis, cause, frequency, clinical patterns and management of liver injury attributable to prescription and nonprescription medications and selected herbal and dietary supplements. The LiverTox site is meant as a resource for both physicians and patients as well as for clinical academicians and researchers who specialize in idiosyncratic drug induced hepatotoxicity.
Dose response for mithramycin (plicamycin) in malignant cell lines. (a) PC3-TR, (b) PC3 human prostate cancer cells, and (c) ... plicamycin) demonstrated the greatest enhancement in loss of cancer cell viability at 6.6 μM (50.5%), 0.66 μM (24.9%) and 0.33 ...
Plicamycin, a chemotherapy used to stop the growth of cancer cells. *Amiodarone, a medication used to treat irregular heart ...
... plicamycin (Mithracin). ...
... plicamycin (Mithracin). ...
  • 2023. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109130/all/plicamycin. (unboundmedicine.com)
  • Plicamycin has been tested in chronic myeloid leukemia. (wikipedia.org)
  • Plicamycin is currently used in multiple areas of research, including cancer cell apoptosis and as a metastasis inhibitor. (wikipedia.org)
  • Plicamycin has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. (wikipedia.org)
  • Plicamycin, which was formerly known as mithramycin, is an antibiotic that is used as an anticancer agent in the therapy of testicular and germ cell cancers. (nih.gov)
  • In rare circumstances, gallium nitrate and you will plicamycin (formerly mithramycin) can be used. (etesbilgisayar.com)
  • Plicamycin has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. (wikipedia.org)
  • 19. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. (nih.gov)
  • Plicamycin is also used to reduce hypercalcemia, especially that due to malignancies. (nih.gov)
  • Plicamycin causes acute hepatic injury that arises within days of starting therapy, but is usually transient and asymptomatic and rarely leads to jaundice. (nih.gov)